Schmid, Hans-Peter; Morant, Rudolf; Bernhard, Jürg; Maibach, Rudolf; Swiss Group for Clinical Cancer Research, (SAKK) (2003). Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma. European urology, 43(1), pp. 28-30. Amsterdam: Elsevier 10.1016/S0302-2838(02)00539-0
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S0302283802005390-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (111kB) |
In hormone refractory prostatic carcinoma (HRPCa), the majority of patients have bone metastases only, which are by definition non-measurable. This makes objective evaluation of chemotherapeutic agents difficult. Prostate specific antigen (PSA) as a dynamic model was analyzed as potential auxiliary end point in HRPCa.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Bernhard, Jürg Theodor |
ISSN: |
0302-2838 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 15:24 |
Last Modified: |
24 Jul 2023 16:09 |
Publisher DOI: |
10.1016/S0302-2838(02)00539-0 |
PubMed ID: |
12507540 |
Web of Science ID: |
000180876000005 |
BORIS DOI: |
10.48350/37818 |
URI: |
https://boris.unibe.ch/id/eprint/37818 (FactScience: 211451) |
Actions (login required)
 |
Edit item |